Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This article evaluates sexual function using the International Index of Erectile Function in people taking finasteride for androgenetic alopecia but does not present new findings.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This case report describes a patient with secondary syphilis exhibiting distinct dermoscopic features, including moth-eaten alopecia and an erythematous background more pronounced than previously reported.

This article discusses the formulation of nanoemulsion systems as advanced drug delivery mechanisms, but it reports no new clinical findings.

The laser comb did not improve hair regrowth in mice with alopecia areata.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This article reviews guidelines for testosterone replacement therapy in late-onset hypogonadism, emphasizing the need for clear indications and appropriate testing before treatment, but provides no new research findings.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study suggests that a low daily dose of finasteride may be effective in reducing recurrent priapism episodes in children and adolescents with sickle cell disease, though larger controlled studies are needed to confirm these findings.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

This special issue contains abstracts from the ASA 40th Annual Meeting, providing an overview of various studies without reporting new primary results.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This review discusses the uses of Achillea millefoilum described by Ibn Rushd, finding scientific support for its applications in treating alopecia and skin disorders.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

The authors updated recommendations on diagnosing and treating women's sexual dysfunctions, emphasizing a comprehensive assessment approach, while noting the need for further multidisciplinary research.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This review discusses the pharmacological properties and therapeutic potential of K+ channel opening compounds, noting their prospective use in treating cardiovascular and respiratory conditions, but reports no new results.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.